Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEXX Laboratories SEC filings document the formal record for a Nasdaq-listed animal-health diagnostics and software company. Form 8-K reports furnish quarterly and annual financial results, operating updates and exhibits tied to the company’s CAG Diagnostics, reference laboratory and veterinary product businesses.
The company’s filings also cover governance and capital-structure matters, including definitive proxy materials, executive compensation, board composition, officer transitions, equity-award disclosures and shareholder meeting items. Other material-event reports describe credit agreement amendments and registered common stock information, providing formal disclosure on IDEXX’s financing arrangements, corporate governance and reporting obligations.
Michael Lane, Executive Vice President of Idexx Laboratories (IDXX), reported multiple stock and option transactions dated 08/06/2025. The filing shows acquisitions of 1,286 and 7,125 shares (prices listed as $206.94 and $288.78), and dispositions of 5,631, 2,480 and 300 shares at weighted-average prices of $627.5634, $627.9911 and $628.8866, respectively. After these transactions the filing reports total direct beneficial ownership of 7,131.9435 shares and an additional 592 shares held indirectly by the reporting person’s spouse in an IRA.
The filing also lists non-qualified stock option awards related to the reporting person: a right associated with 1,286 underlying shares (exercise price $206.94) and a right associated with 7,125 underlying shares (exercise price $288.78). Explanations note prior grants exercisable in installments beginning in 2020 and 2021 and purchases of 28.7090 shares under the issuer’s Employee Stock Purchase Plan.
IDEXX Laboratories Inc. filed a Form 144 to register the proposed sale of 5,450 shares of common stock, with an aggregate market value of $3,551,220.00, to be sold on NASDAQ through Morgan Stanley Smith Barney LLC. The filing lists 80,004,694 shares outstanding and shows an approximate sale date of 08/08/2025.
The shares were acquired via a stock option exercise on 08/08/2025 and paid in cash. The filer reports "Nothing to Report" for securities sold during the past three months and includes the standard attestation about material nonpublic information and trading-plan language. The provided content does not show a populated notice date or signature block.
Form 144 summary for IDEXX Laboratories, Inc. (IDXX)
This Form 144 reports a proposed sale of 7,143 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $4,503,160.87. Shares outstanding are listed as 80,004,694. The approximate date of sale is 08/06/2025.
The securities were acquired by stock option exercise on 08/06/2025 from the issuer and payment is listed as cash. The filing states "Nothing to Report" for securities sold during the past three months. Several filer and issuer contact fields (CIK, submission contact name/phone/email, date of notice, signature) are not provided in the extract.